Krishnansu S. Tewari, MD
A multipronged attack on the tumor vasculature network is at the heart of a recently launched clinical trial aimed at developing new therapeutic options for women with advanced, recurrent, platinum-resistant ovarian cancer.
The novel agent fosbretabulin tromethamine is being combined with bevacizumab (Avastin) and physician’s choice of either paclitaxel or pegylated liposomal doxorubicin in the experimental arm of the phase II/III FOCUS study (NCT02641639). The regimen will be compared with bevacizumab plus chemotherapy, which is one option for this patient population.
Fosbretabulin and bevacizumab both target vascular signaling but in different ways, said principal investigator Krishnansu S. Tewari, MD, a full professor and director of research in the Division of Gynecologic Oncology at the University of California, Irvine and director of the Gynecologic Oncology Program at the Center for Cancer Prevention and Treatment at St. Joseph's Hospital in Orange, California.
“Bevacizumab prevents the formation of new blood vessels whereas fosbretabulin targets existing vasculature,” Tewari said in an interview with OncLive
. “The central part of the tumor undergoes necrosis because the existing vasculature is targeted. Meanwhile, out on the periphery or the rim of the tumor, bevacizumab is working to prevent new blood vessels from forming. So it’s a double attack on vasculature. Hence the terminology, vascular-targeting therapy."
That dual attack will be combined with chemotherapy, which is aimed at direct killing of cancer cells. “Hopefully, the regimen will be one concerted effort to target the cancer and therefore limit the toxicity to the patient,” said Tewari.
Rationale for Combination
Fosbretabulin is a small molecule derived from combretastatin A4 phosphate (CA4P), originally isolated from the African bush willow Combretum caffrum
Specifically, fosbretabulin is classified as a vascular disrupting agent that selectively binds to β-tubulin and changes the shape of recently formed endothelial cells without affecting more mature cells.2
In contrast, bevacizumab is a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), preventing it from interacting with VEGF receptors on the surface of endothelial cells.3
It is categorized as an antiangiogenic agent.
The rationale for combining the 2 vascular-targeting drugs was established in the single-arm phase II GOG-01861 study, conducted in 107 patients with recurrent or persistent epithelial ovarian, tubal, or peritoneal carcinoma who had undergone ≤3 prior treatments.1
Participants were randomized to receive bevacizumab (15 mg/kg) plus fosbretabulin (60 mg/m2
) intravenously once every 3 weeks versus bevacizumab alone.
The regimen demonstrated a median progression-free survival of 7.3 months compared with 4.8 months for bevacizumab alone (HR, 0.69; P
= .05). The overall response rate among patients with measurable disease as defined by RECIST criteria was 35.7% among participants treated with the combination (n = 42) versus 28.2% among those who received bevacizumab alone (n = 39).1
In terms of adverse events, the combination did not result in any unexpected signals, Tewari said. Grade 3 hypertension was observed more in the combination arm.
Tewari stressed that investigators would be watching carefully for cardiovascular side effects including hypertension and sinus tachycardia among patients who receive both vascular-targeting drugs. He said they have developed algorithms to address potential cardiovascular side effects.
Hypertension also is a concern with bevacizumab.
The FOCUS study will be conducted in 2 stages. In the first part, 80 patients will be randomized to the experimental 3-drug regimen versus the control; up to 4 interim analyses will be conducted so that researchers can determine the safety and efficacy of the novel strategy. The second part of the study will randomize approximately 350 patients to the same treatment arms.
Participants will be stratified by the type of chemotherapy they receive, the duration of platinum-free interval (<3 vs 3-6 months) before enrolling in the trial, and the line of therapy (2nd vs 3rd).
The trial is open to women aged 18 years and older with confirmed platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received ≥1 prior platinum-based regimens and have measurable disease. Participants receiving doxorubicin must have left ventricular ejection fraction ≥45% at baseline assessment.